IG
IGS1.F India Globalization Capital Inc
- Market cap
- EUR 20.9M
- P/E
- -
- P/B
- 3.68x
- ROE
- -107.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Mar 2026.
Is IGS1.F undervalued?
Graham numberThe Graham number of India Globalization Capital Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
India Globalization Capital Inc fundamental analysis
No fundamental analysis for India Globalization Capital Inc yet.
India Globalization Capital Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, th…
Full company profileIndia Globalization Capital Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 4 quarters up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
India Globalization Capital Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.37M | 580K | 2.19M | 5.12M | 4.07M | 898K | 397K | 911K | 1.35M | 1.27M | 1.19M |
| Gross Profit | 843K | 218K | 81.5K | 132K | 115K | 113K | 194K | 442K | 733K | 619K | 352K |
| Operating Income | -2.59M | -2.05M | -1.79M | -4.64M | -6.86M | -8.72M | -15.4M | -11.6M | -9.80M | -7.45M | -10.2M |
| EBITDA | - | - | -1.74M | -4.58M | -6.72M | -8.25M | -14.8M | -10.9M | -9.16M | -6.98M | -9.82M |
| Net Income | -2.81M | -1.87M | -1.79M | -4.10M | -7.32M | -8.81M | -15.0M | -11.5M | -13.0M | -7.12M | -6.55M |
| EPS | - | -0.07 | -0.06 | -0.10 | -0.19 | -0.18 | -0.29 | -0.22 | -0.19 | -0.09 | -0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 18.9M | 11.3M | 10.9M | 34.5M | 29.0M | 35.9M | 26.8M | 17.2M | 9.90M | 8.75M | 9.19M |
| Total Liabilities | 4.91M | 3.93M | 2.79M | 893K | 2.45M | 3.06M | 2.94M | 2.27M | 2.58M | 2.42M | 3.06M |
| Shareholders' Equity | 13.5M | 7.36M | 8.06M | 33.6M | 26.5M | 32.8M | 23.9M | 14.9M | 7.32M | 6.33M | 6.12M |
| Cash & Short-term Investments | 1.49M | 538K | 1.66M | 25.6M | 7.26M | 14.5M | 10.5M | 3.20M | 1.20M | 405K | 207K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -158K | -1.39M | -1.93M | -3.33M | -8.68M | -10.8M | -7.46M | -7.05M | -5.20M | -4.07M | - |
| Capital Expenditure | 122K | 146K | 136K | 15.0K | 4.39M | 1.47M | 207K | 228K | 515K | 316K | 0.00 |
| Free Cash Flow | - | - | -2.13M | -3.39M | -13.1M | -12.4M | -8.20M | -7.67M | -5.71M | -4.38M | - |
| Ratios | |||||||||||
| ROE | -20.8% | -25.4% | -22.1% | -12.2% | -27.6% | -26.9% | -62.8% | -77.2% | -177.6% | -112.5% | -107.0% |
| ROA | -14.9% | -16.5% | -16.5% | -11.9% | -25.2% | -24.6% | -56.0% | -67.0% | -131.3% | -81.4% | -71.3% |
| Net Profit Margin | -44.1% | -321.7% | -81.5% | -80.1% | -179.6% | -981.2% | -3,782.4% | -1,263.0% | -966.5% | -560.3% | -552.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
India Globalization Capital Inc dividends
India Globalization Capital Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Apr 19, 2013.
Who owns India Globalization Capital Inc
- Insiders 9.17%
- Institutions 19.75%
- Public & others 71.08%
- Shares outstanding 117M
- Free float 92.4M
India Globalization Capital Inc company profile
- Company name
- India Globalization Capital Inc
- Ticker
- IGS1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 70
- Fiscal year end
- March
- Address
- 10224 Falls Road, Potomac, MD, United States, 20854
- Phone
- 301 983 0998
- Website
- igcpharma.com
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
India Globalization Capital Inc management
4- Mr. Ram MukundaFounder, President, CEO & Director · born 1959
- Ms. Claudia GrimaldiVP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director · born 1971
- Benysh Qureshi Esq., M.B.A.Director of Operations
- Mr. Rohit Goel CPA, M.B.A.Director of Accounting & Senior Director · born 1994